Results 161 to 170 of about 8,627 (176)

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I

Journal of Thrombosis and Haemostasis, 2004
O E Dahl, B I Eriksson
exaly  

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Journal of Thrombosis and Haemostasis, 2007
O E Dahl, B I Eriksson, H R Buller
exaly  

Coadministration of Dabigatran Etexilate and Atorvastatin

American Journal of Cardiovascular Drugs, 2012
Joachim Stangier
exaly  

Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials

Journal of the American Heart Association, 2014
Jean-Yves Reginster, François Mullier, Valentine Minet   +2 more
exaly  

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

British Journal of Clinical Pharmacology, 2007
exaly  

New therapeutic option for thromboembolism – dabigatran etexilate

Expert Opinion on Pharmacotherapy, 2008
Masahiro Ieko
exaly  

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

Drugs, 2017
exaly  

Dabigatran-etexilate

Reactions Weekly, 2016
openaire   +1 more source

Rash Associated with Dabigatran Etexilate

Pharmacotherapy, 2013
exaly  

Dabigatran etexilate: A novel oral direct thrombin inhibitor

American Journal of Health-System Pharmacy, 2011
exaly